MetaCap

Pfizer (PFE) vs Takeda Pharmaceutical (TAK)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Takeda Pharmaceutical (TAK) has outperformed Pfizer (PFE) over the past year, gaining 52.2% versus a gain of 9.4%. Over five years, TAK leads with a +60.9% price change compared with -49.3% for PFE. Pfizer is the larger company by market cap ($156.18 billion vs $69.55 billion), about 2.2 times the size.

On valuation, Pfizer trades at a lower forward P/E (9.3x vs 41.1x for Takeda Pharmaceutical). Takeda Pharmaceutical offers the higher dividend yield (927.88% vs 7.85%).

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

PFE+9.42%TAK+52.24%
+55%+23%-8%
Nov 21, 20251 yearNov 20, 2026
PFE-46.06%TAK+55.39%
+61%-1%-62%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

PFE versus TAK key metrics
MetricPFETAK
Share price$27.40$21.77
Market cap$156.18B$69.55B
1-day change-0.51%+1.68%
YTD return+10.04%+39.64%
1-year return+9.42%+52.24%
5-year return-49.26%+60.90%
P/E ratio (TTM)39.14311.00
Forward P/E9.2841.08
EPS (TTM)$0.70$0.07
Dividend yield7.85%927.88%
Annual dividend$2.15$202.00
Revenue (latest FY)$62.58B—
Revenue growth (YoY)-1.65%—
Net income (latest FY)$7.77B—
Gross margin74.33%—
Net margin12.42%—
52-week high$31.44$22.07
52-week low$23.62$14.16
Distance from 52-week high-12.85%-1.36%
Analyst consensusbuystrong_buy
Avg. price target upside+10.29%+12.68%
Average volume33.52M2.73M
Shares outstanding5.70B3.19B
Employees75,00047,029
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Pfizer is about 2.2 times larger than Takeda Pharmaceutical by market value ($156.18B vs $69.55B).
  • TAK has outperformed PFE by 42.8 percentage points over the past year.
  • Takeda Pharmaceutical trades at a higher earnings multiple (311.0x vs 39.1x trailing P/E).
  • Takeda Pharmaceutical offers a meaningfully higher dividend yield (927.88% vs 7.85%).

About Pfizer

PFE stock →

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

Health Care · Biotechnology: Pharmaceutical Preparations · 75,000 employees

About Takeda Pharmaceutical

TAK stock →

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, oncology, vaccines, and neuroscience.

Health Care · Biotechnology: Pharmaceutical Preparations · 47,029 employees

PFE vs TAK FAQ

Which is bigger, Pfizer or Takeda Pharmaceutical?

Pfizer (PFE) is larger, with a market capitalization of $156.18B compared with $69.55B for Takeda Pharmaceutical (TAK).

Which stock has performed better over the past year, PFE or TAK?

TAK returned +52.24% over the past 12 months, compared with +9.42% for PFE (price return, excluding dividends). Past performance does not predict future results.

Which has the lower P/E ratio, PFE or TAK?

PFE has the lower trailing P/E at 39.1, versus 311.0 for TAK. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.

Which pays a higher dividend, Pfizer or Takeda Pharmaceutical?

Takeda Pharmaceutical has the higher yield at 927.88%, compared with 7.85% for Pfizer.

Are Pfizer and Takeda Pharmaceutical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons